Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
not yet recruiting

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

key information

study id #: NCT03340675

condition: Duchenne Muscular Dystrophy Cardiomyopathy

status: not yet recruiting


Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD.

intervention: Ifetroban, Placebos

mechanism of action: Thromboxane receptor antagonist to prevent cardiac function deterioration

results: https://clinicaltrials.gov/ct2/show/results/NCT03340675

last updated: November 21, 2018

study details

start date: February 2019

estimated completion: December 2021

phase of development: Phase 2

size / enrollment: 48

study description:
This is a phase 2 randomized, double-blind, placebo-controlled, multiple dose study to determine the safety, pharmacokinetics and efficacy of two doses of oral ifetroban in subjects with DMD. DMD patients who meet the inclusion criteria and none of the exclusion criteria will receive oral ifetroban or placebo once daily for 12 months. Subjects will be enrolled onto one of three treatment groups, low-dose ifetroban, high-dose ifetroban or placebo. Each dose level will be evaluated by eight subjects with early stage (7-15 yo) DMD and eight subjects with advanced stage (16+ yo) DMD as there may be differences in the amount and rate of drug absorption. Each subject treated will be evaluated for first-dose and steady-state exposure PK. All subjects who receive treatment will be assessed for safety. All subjects with at least one efficacy assessment post-baseline will be evaluated for efficacy. Blood and urine will be collected for standard and novel cardiac biomarkers.

primary outcomes:

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [Time Frame: Baseline through 12 months]
    Number of subjects with one or more treatment emergent adverse event

secondary outcomes:

  • Pharmacokinetics [Time Frame: Day 0 and Day 7]
    Peak plasma concentration of ifetroban and its acyl glucuronide metabolite after administration.
  • Change from baseline in left ventricular ejection fraction [Time Frame: Baseline and 12 months]
    There should be no change in left ventricular ejection fraction. Patients with DMD have a decline.
  • Change from baseline in pulmonary function [Time Frame: Baseline and 12 months]
    Change from baseline in forced expiratory volume in 1 second
  • Change from baseline in quality-of-life [Time Frame: Baseline and 12 months]
    The 23 items PedQL measure these core dimensions of health as delineated by the World Health Organization, as well as role (school) functioning. Items measured include:
    1) Physical Functioning (8 items),
    2) Emotional Functioning (5 items),
    3) Social Functioning (5 items),and
    4) School Functioning (5 items).
    Each item is measured on a 5 point Likert scale with 0 indicating never and 4 indicating almost always. The Likert scores are reversed scored and linearly transform to a 0-100 scale with 0=100, 1-75, 2=50, 5=25, and 4=0. A higher score indicates better health-related quality of life.

inclusion criteria:
• Males 7 years of age and older with the diagnosis of DMD, defined as phenotype consistent with DMD and either positive genotype, first degree relative with positive genotype, or confirmatory muscle biopsy.
• Stable dose of oral corticosteroids for at least 12 weeks or has not received corticosteroids for at least 12 weeks.
• Stable cardiac function defined as change in LVEF of < 15% and no heart failure admission over the last 12 months; LVEF 35% or greater by cine CMR or echocardiography; myocardial damage in one or more left ventricular segments evident by late gadolinium enhancement allowed; concurrent angiotensin-converting enzyme inhibitors (ACEI), beta-blocker (BB) or angiotensin receptor blocker (ARB) therapy allowed (selection of which dictated by clinical care) if started three months or greater from first dose of investigational medicinal product (IMP) without change in dose. Aldosterone receptor antagonists (e.g. spironolactone or eplerenone) allowed if started 12 months or greater from first dose of IMP. No changes throughout the study allowed.
• Use of contraceptives for sexually active males throughout the study
• Subjects aged 18 years and older, informed consent obtained directly. For subjects ages 7-17 years, both assent from the subject and permission from a parent or guardian.

exclusion criteria:
• Clinically significant illness other than DMD
• Clinically significant laboratory abnormality not associated with DMD
• Major surgery within six weeks prior to the first dose of study drug, or planned surgery during this study which would interfere with the ability to perform study procedures
• Require anti-arrhythmic therapy and/or initiation of diuretic therapy for management of acute heart failure in the last 6 months
• A LVEF of < 35% by CMR and/or fractional shortening of < 15% based on echocardiography (ECHO) during screening
• Concurrent use of nitrates, alpha-adrenergic receptor blockers, or phosphodiesterase inhibitors
• A known bleeding disorder or has received chronic anticoagulant treatment within two weeks of study entry
• Allergy to gadolinium contrast or known renal insufficiency defined as creatinine above the upper limit of normal for age. The male serum reference ranges as follows:
Age 7-9 years - 0.2 - 0.6 mg/dL
Age 10-11 years - 0.3 - 0.7 mg/dL
Age 12-13 years - 0.4 - 0.8 mg/dL
Age 14-15 years - 0.5 - 0.9 mg/dL
Age 16 years or older - 0.8 - 1.3 mg/dL
• Non-MR compatible implants (e.g. neurostimulator, automatic implantable cardioverter-defibrillator [AICD])
• Any other condition that could interfere with the subject's participation

study contacts

sponsor: Cumberland Pharmaceuticals

contacts: Ines M Macias-Perez (PhD), 6159795778, imaciasperez@cumberlandpharma.com;
Byron Kaelin (RN), 6156274121, bkaelin@cumberlandpharma.com

investigators: Larry Markham, MD